DBV Technologies Reports Widened First-Quarter Loss

By Chris Stiles • Monday, May 04 11:02 • Permanent Link

DBV Technologies widened its first-quarter loss as spending rose sharply on clinical work and U.S. launch preparation, while cash increased after financing activity.

Net loss for the three months ended March 31, 2026, was $47.6 million, up from $27.1 million a year earlier. Loss from operations deepened to $47.9 million from $26.6 million.

Revenue was minimal in both periods, with operating income of $0.9 million in the latest quarter versus $0.8 million a year ago, reflecting a French research tax credit.

Research and development expense climbed to $33.4 million from $21.5 million, an increase of $11.9 million. DBV said the higher spend was driven by recruitment for the Comfort Toddlers study, the VITESSE open-label extension, faster biologics license application readiness work, added U.S. medical affairs, quality and regulatory staffing, and pre-commercial inventory build.

Selling and marketing expense rose to $4.8 million from $0.3 million, while general and administrative expense increased to $10.5 million from $5.6 million. Total operating expenses reached $48.8 million, compared with $27.4 million in the prior-year quarter.

Financial income turned positive at $0.5 million from a $0.5 million expense a year earlier, and loss before taxes narrowed slightly to $47.4 million from $27.1 million after the tax line. Net loss per share improved to $(0.11) from $(0.26), helped by a larger equity base after recent financings.

Cash and cash equivalents rose to $229 million at March 31, 2026, from $194 million at December 31, 2025. Net cash used in operating activities was $49 million, up from $20 million in the first quarter of 2025. Financing activities provided $89 million in the quarter, tied to the full exercise of ABSA and BS warrants from the March 2025 private placement.

DBV said the cash balance is expected to fund operations into the second quarter of 2027. As a result of these announcements, the company's shares have moved 2.38% on the market, and are now trading at a price of $19.80. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.